Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
The High Court of England and Wales has shifted the momentum of the spat, with the EPO Technical Board of Appeal set to hear a related case tomorrow
Opinion: Popular attacks on America’s life sciences patent system are highly misleading
18 March 2023
Surprise intervention of US government has not helped the mRNA company
17 March 2023
Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112
15 March 2023
The takeover of the biopharma innovator is the largest pharma sector deal since 2019
14 March 2023
Questions over FDA patent listing remain following Jazz v Avadel dispute
09 March 2023
Potential initiatives to limit continuation practice are causing deep divides in the life sciences patent community – causing technology licensors and Big Tech to take sides
07 March 2023
Highly-litigated intellectual property to feature in yet another dispute
07 March 2023
Saturday Opinion: Disseminating covid diagnostics and therapeutics is critical, but attempting to do so via the TRIPS waiver extension is rife with unintended consequences
04 March 2023
The USPTO director shares her thoughts on life sciences IP rights and ongoing collaboration with the FDA
02 March 2023
The vaccine maker has paid for use of state-owned IP, but several points of contention remain
28 February 2023
Unlock unlimited access to all IAM content